
Abbott Labs (ABT) Stock Forecast & Price Target
Abbott Labs (ABT) Analyst Ratings
Bulls say
Abbott Laboratories recorded a robust sales performance, with Nutrition sales reaching $2.15 billion, representing a 6.8% year-over-year organic growth that exceeded consensus expectations. The company's Structural Heart portfolio showcased remarkable resilience, with an organic growth of 14.7%, further indicating strong market adoption and an anticipated continuation of growth in the teens. Additionally, Abbott's commitment to dividends, having increased for over 50 consecutive years, reinforces investor confidence alongside an optimistic outlook for organic sales growth projected at 7.5-8.5% for 2025.
Bears say
Abbott Laboratories has experienced a notable decline in diagnostics revenue, reporting $2.054 billion, which fell short of expectations due to lower-than-anticipated COVID-19 testing sales and adverse impacts from volume-based procurement programs in China. First-quarter 2025 sales of $10.36 billion, while showing a year-over-year increase, slightly missed projections due to the same COVID-related issues and soft performance in diagnostics products. Additionally, macroeconomic pressures such as inflation, foreign exchange challenges, and potential regulatory hurdles present significant risks that may hinder Abbott's growth and earnings potential moving forward.
This aggregate rating is based on analysts' research of Abbott Labs and is not a guaranteed prediction by Public.com or investment advice.
Abbott Labs (ABT) Analyst Forecast & Price Prediction
Start investing in Abbott Labs (ABT)
Order type
Buy in
Order amount
Est. shares
0 shares